Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 31,358 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose 2 Clear all
Completed Phase 4 Interventional

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

NCT00418600
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol® (doxercalciferol capsules), doxercalciferol capsules, Hectorol®, doxercalciferol capsules, Hectorol® capsules
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Hot Springs, Arkansas • Downey, California • Tarzana, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 22, 2026, 4:06 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311
View directory record Official record
Conditions
Gastroesophageal Cancer
Interventions
Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel, Rescue medications, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS

NCT00844844
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 22, 2026, 4:06 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis

NCT02424734
View directory record Official record
Conditions
Late-onset Sepsis
Interventions
Ceftaroline Fosamil, Ampicillin, Aminoglycoside
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Days to 59 Days
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

NCT01626664
View directory record Official record
Conditions
Adult T-cell Leukemia-Lymphoma
Interventions
KW-0761, Pralatrexate, gemcitabine plus oxaliplatin, DHAP
Biological · Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Results available

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

NCT04608409
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Lapatinib and Paclitaxel
Drug
Lead sponsor
Frederick R. Ueland, M.D.
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B

NCT02418793
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
MOD-5014
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

NCT04191421
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Siltuximab, Spartalizumab
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

NCT01352793
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
rLP2086 vaccine, control
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years
Enrollment
5,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
39
States / cities
Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

NCT00132314
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia
Interventions
IM risperidone, oral antipsychotic medication
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
19
States / cities
Tuscaloosa, Alabama • Long Beach, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

NCT01974895
View directory record Official record
Conditions
Influenza
Interventions
FluLaval® Quadrivalent, Fluzone®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
12
States / cities
Sacramento, California • West Covina, California • Altamonte Springs, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 4 Interventional Results available

Benzocaine Gel Toothache Dose-Response Study

NCT00474175
View directory record Official record
Conditions
Toothache
Interventions
Placebo gel, benzocaine
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
12 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 22, 2026, 4:06 AM EDT
Terminated Phase 2 Interventional Results available

Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver

NCT01030757
View directory record Official record
Conditions
Liver Cancer
Interventions
Tomotherapy treatment
Radiation
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

NCT01327612
View directory record Official record
Conditions
Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced, Lymphoma, Metastatic Cancer, Non-Small Cell Lung Cancer, Sarcoma, Solid Tumors
Interventions
Modified FOLFOX6, Conatumumab, Ganitumab, Bevacizumab
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
10
States / cities
Duarte, California • La Jolla, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

NCT05004181
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
Interventions
BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7), Monovalent BNT162b2 (B.1.617.2), Monovalent BNT162b2 (B.1.1.529.1), Observational
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
14
States / cities
Long Beach, California • San Diego, California • Milford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 22, 2026, 4:06 AM EDT
Withdrawn Phase 2 Interventional

Randomized Phase II Trial of Chemoembolization and Sorafenib

NCT02908165
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
conventional TACE in combination with sorafenib, administered on a continuous schedule, conventional TACE in combination with sorafenib, administered on a sequential schedule
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Results available

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

NCT03704467
View directory record Official record
Conditions
Ovarian Cancer
Interventions
M6620, Avelumab, Carboplatin
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
7
States / cities
Greenbrae, California • Stamford, Connecticut • Saginaw, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 22, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RO7837195, RO7837195 Matched Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers

NCT01952444
View directory record Official record
Conditions
Inhalational Anthrax
Interventions
ETI-204, Ciprofloxacin
Biological · Drug
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 22, 2026, 4:06 AM EDT
Withdrawn Phase 4 Interventional

Administration of Prazosin to Prevent PTSD in Adult Women After Sexual Assault

NCT03997864
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Prazosin, Placebos
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

NOLAN: Naproxen or Loratadine and Neulasta

NCT01712009
View directory record Official record
Conditions
Bone Pain in Stage I - III Breast Cancer
Interventions
Naproxen, Loratadine, Pegfilgrastim, Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
83
States / cities
Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 22, 2026, 4:06 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig (ABBV-383)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
27
States / cities
Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 4:06 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location

NCT05839899
View directory record Official record
Conditions
Abortion
Interventions
Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol
Drug
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 22, 2026, 4:06 AM EDT
Completed Early Phase 1 Interventional

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

NCT03358563
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Degarelix, Bicalutamide, Ferumoxytol-enhanced MRI imaging
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 22, 2026, 4:06 AM EDT